iBio Inc (IBIO)
1.98
+0.17
(+9.39%)
USD |
NYAM |
May 17, 16:00
1.98
0.00 (0.00%)
After-Hours: 20:00
iBio Research and Development Expense (TTM): 8.141M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.141M |
| September 30, 2023 | 9.385M |
| June 30, 2023 | 10.33M |
| March 31, 2023 | 11.53M |
| December 31, 2022 | 12.16M |
| September 30, 2022 | 11.24M |
| June 30, 2022 | 9.827M |
| March 31, 2022 | 9.362M |
| December 31, 2021 | 8.252M |
| September 30, 2021 | 8.767M |
| June 30, 2021 | 9.495M |
| March 31, 2021 | 6.981M |
| December 31, 2020 | 5.914M |
| September 30, 2020 | 4.428M |
| June 30, 2020 | 3.543M |
| March 31, 2020 | 4.584M |
| December 31, 2019 | 4.942M |
| September 30, 2019 | 5.327M |
| June 30, 2019 | 5.474M |
| March 31, 2019 | 4.892M |
| December 31, 2018 | 4.405M |
| September 30, 2018 | 4.125M |
| June 30, 2018 | 3.986M |
| March 31, 2018 | 4.056M |
| December 31, 2017 | 4.226M |
| Date | Value |
|---|---|
| September 30, 2017 | 4.282M |
| June 30, 2017 | 4.117M |
| March 31, 2017 | 3.858M |
| December 31, 2016 | 3.77M |
| September 30, 2016 | 3.425M |
| June 30, 2016 | 3.156M |
| March 31, 2016 | 3.067M |
| December 31, 2015 | 2.834M |
| September 30, 2015 | 2.861M |
| June 30, 2015 | 3.495M |
| March 31, 2015 | 2.142M |
| December 31, 2014 | 1.67M |
| September 30, 2014 | 1.524M |
| June 30, 2014 | -0.15M |
| March 31, 2014 | 1.406M |
| December 31, 2013 | 1.694M |
| September 30, 2013 | 1.765M |
| June 30, 2013 | 3.431M |
| March 31, 2013 | 3.519M |
| December 31, 2012 | 4.195M |
| September 30, 2012 | 4.701M |
| June 30, 2012 | 4.981M |
| March 31, 2012 | 5.095M |
| December 31, 2011 | 4.925M |
| September 30, 2011 | 4.383M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
3.543M
Minimum
Jun 2020
12.16M
Maximum
Dec 2022
7.878M
Average
8.252M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Lixte Biotechnology Holdings Inc | 0.8281M |
| PAVmed Inc | 12.17M |
| Avalo Therapeutics Inc | 9.89M |
| Imunon Inc | 11.96M |
| Ocugen Inc | 36.84M |